Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
BERLIN, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pentixapharm AG, a developer of innovative radiopharmaceuticals, receives 6.77 million Euro for intangible assets formerly developed by Glycotope from undisclosed Asian pharma and biotech companies. The transaction …